Mycosis fungoides report of the 2011 society for hematopathology/European association for haematopathology workshop

American Journal of Clinical Pathology

Volumn 139, Issue 4, 2013, Pages 466-490

  Song, Sophie X ^a   Willemze, Rein ^b   Swerdlow, Steven H ^c   Kinney, Marsha C ^d   Said, Jonathan W ^a  

^a UCLA MEDICAL CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cutaneous T cell lymphoma; Mycosis fungoides; S zary syndrome

Indexed keywords

CD30 ANTIGEN;

ARTICLE; BONE MARROW BIOPSY; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SOCIETY; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGNOSIS; SEZARY SYNDROME; SKIN BIOPSY; T LYMPHOCYTE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; SKIN TUMOR;

HUMANS; MYCOSIS FUNGOIDES; SKIN NEOPLASMS;

MLCS; MLOWN;

EID: 84877297519     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPOBDP2OQAJ5BR     Document Type: Article

References (69)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
2. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
3. Ralfkiaer E, Cerroni L, Sander CA, et al. Mycosis fungoides. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:296-298.
4. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857-866.
5. Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sézary syndrome. Lancet. 2008;371:945-957.
6. Pope E, Weitzman S, Ngan B, et al. Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg. 2010;14:1-6.
7. Massone C, Kodama K, Kerl H, et al. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol. 2005;29:550-560.
8. Krejsgaard T, Odum N, Geisler C, et al. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia. 2012;26:424-432.
9. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978-1988.
10. Wada DA, Wilcox RA, Weenig RH, et al. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. J Cutan Pathol. 2010;37:535-541.
11. Hallermann C, Niermann C, Schulze HJ. Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides. Eur J Haematol. 2007;78:260-263.
12. Banham AH, Brown PJ, Lyne L, et al. Is FOXP3 expressed in cutaneous T-cell lymphomas? Eur J Haematol. 2008;80:90-91.
13. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007;21:2512-2518.
14. Ralfkiaer E. Immunohistological markers for the diagnosis of cutaneous lymphomas. Semin Diagn Pathol. 1991;8:62-72.
15. Smoller BR, Bishop K, Glusac EJ, et al. Reassessment of lymphocyte immunophenotyping in the diagnosis of patch and plaque stage lesions of mycosis fungoides. Appl Immunohistochem. 1995;3:32-36.
16. Massone C, Crisman G, Kerl H, et al. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol. 2008;159:881-886.
17. Nikolaou VA, Papadavid E, Katsambas A, et al. Clinical characteristics and course of CD8+ cytotoxic variant of mycosis fungoides: a case series of seven patients. Br J Dermatol. 2009;161:826-830.
18. El-Shabrawi-Caelen L, Cerroni L, Medeiros LJ, et al. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am J Surg Pathol. 2002;26:450-457.
19. Crowley JJ, Nikko A, Varghese A, et al. Mycosis fungoides in young patients: clinical characteristics and outcome. J Am Acad Dermatol. 1998;38:696-701.
20. Wain EM, Orchard GE, Whittaker SJ, et al. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer. 2003;98:2282-2290.
21. Pavlovsky L, Mimouni D, Amitay-Laish I, et al. Hyperpigmented mycosis fungoides: an unusual variant of cutaneous T-cell lymphoma with a frequent CD8+ phenotype. J Am Acad Dermatol. 2012;67:69-75.
22. Zhang B, Beck AH, Taube JM, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffinembedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn. 2010;12:320-327.
23. Langerak AW, Groenen PJTA, Brüggemann M, et al. EuroClonality/ BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012; 26:2159-2171.
24. Thurber SE, Zhang B, Kim YH, et al. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007;57:782-790.
25. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053-1063.
26. Ferrara G, Di Blasi A, Zalaudek I, et al. Regarding the algorithm for the diagnosis of early mycosis fungoides proposed by the International Society for Cutaneous Lymphomas: suggestions from routine histopathology practice. J Cutan Pathol. 2008;35:549-553.
27. Candiago E, Marocolo D, Manganoni MA, et al. Nonlymphoid intraepidermal mononuclear cell collections (pseudo-Pautrier abscesses): a morphologic and immunophenotypical characterization. Am J Dermatopathol. 2000;22:1-6.
28. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): a review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am J Surg Pathol. 1994;18:645-667.
29. Quintanilla-Martinez L, Jansen PM, Kinney MC, et al. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology Workshop. Am J Clin Pathol. 2013;139;491-514.
30. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483-492.
31. Sarantopoulos GP, Palla B, Said J, et al. Mimics of cutaneous lymphoma: report of the 2011 Society for Hematopathology/European Association for Haematopathology Workshop. Am J Clin Pathol. 2013;139:536-551.
32. Heald PW, Glusac EJ. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J Am Acad Dermatol. 2000;42:283-285.
33. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722.
34. Cerroni L, Rieger E, Hodl S, et al. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol. 1992;16:543-552.
35. Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150-1159.
36. Vergier B, de Muret A, Beylot-Barry M, et al, for the French Study Group of Cutaneous Lymphomas. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood. 2000;95:2212-2218.
37. Barberio E, Thomas L, Skowron F, et al. Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol. 2007;157:284-289.
38. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112:3082-3087.
39. Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol. 1988;132:265-277.
40. Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119:1643-1649.
41. Vonderheid EC, Tam DW, Johnson WC, et al. Prognostic significance of cytomorphology in the cutaneous T-cell lymphomas. Cancer. 1981;47:119-125.
42. Benner MF, Jansen PM, Meijer CJLM, et al. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2009;161:121-127.
43. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27:1513-1522.
44. Song JY, Strom T, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD30, CD15, and CD20. J Clin Oncol. 2011;29:e789-e791.
45. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.
46. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126:596-602.
47. Abbott RA, Sahni D, Robson A, et al. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features. J Am Acad Dermatol. 2011;65:313-319.
48. Gallardo F, Costa C, Bellosillo B, et al. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases. Acta Derm Venereol. 2004;84:463-468.
49. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730-4739.
50. Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol. 2010;130:816-825.
51. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24:596-605.
52. Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: description of 9 cases. Am J Surg Pathol. 2010;34:1168-1175.
53. Cho-Vega JH, Tschen JA, Duvic M, et al. Early-stage mycosis fungoides variants: case-based review. Ann Diagn Pathol. 2010;14:369-385.
54. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138:191-198.
55. Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones. Arch Dermatol. 2007;143:921-932.
56. Haghighi B, Smoller BR, LeBoit PE, et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000;13:502-510.
57. Lee J, Viakhireva N, Cesca C, et al. Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. J Am Acad Dermatol. 2008;59:706-712.
58. Kempf W, Ostheeren-Michaelis S, Paulli M, et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization for Research and Treatment of Cancer (EORTC). Arch Dermatol. 2008;144:1609-1617.
59. Ralfkiaer E, Willemze R, Whittaker SJ. Sézary syndrome. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:299.
60. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95-106.
61. Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146:1382-1388.
62. Wada DA, Wilcox RA, Harrington SM, et al. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome. Am J Hematol. 2011;86:325-327.
63. Cetinözman F, Jansen PM, Vermeer MH, et al. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. 2012;148:1379-1385.
64. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+CD26-subset in the identification of circulating Sézary cells. Br J Dermatol. 2001;144:125-135.
65. Jones D, Dang NH, Duvic M, et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885-892.
66. Vaughan J, Harrington AM, Hari PN, et al. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. Am J Clin Pathol. 2012;137:403-411.
67. Fierro MT, Novelli M, Quaglino P, et al. Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma. Dermatology. 2008;216:213-221.
68. Campbell JJ, Clark RA, Watanabe R, et al. Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767-771.
69. Nagler AR, Samimi S, Schaffer A, et al. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome. J Am Acad Dermatol. 2012;66:503-508.